JAK Inhibitors Could Face Scrutiny Over Cholesterol Effects
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As positive efficacy data rolls in for the janus kinase inhibitors in rheumatoid arthritis, like Pfizer’s Phase III tasocitinib, elevated lipid levels are emerging as an issue worth keeping an eye on.